Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 1618 Print this page  Email this page Small font size Default font size Increase font size
Year : 2007  |  Volume : 22  |  Issue : 1  |  Page : 1-8

Pretargeting in radio bio-conjugate therapy: with reference to "rhenium, gold & lutetium as candidate therapy isotopes"

1 Nuclear Medicine & RIA unit P.G. Dept. of Medicine, S. N. Medical College, Agra, India
2 Department of Chemical Sciences, St. John's College, Agra, India

Correspondence Address:
D K Hazra
12/123, Nai Ki Mandi, Katra Hathi Shah, Agra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Radiobioconjugate therapy is an emerging modality for Cancer in addition to conventional surgery, chemotherapy & external radio-therapy. The central problem of radio-bioconjugate therapy is the small fraction of radio-bioconjugate localized in the tumour. Pretargeting is one approach to maximize targeting in which an antibody construct, having a dual affinity both for tumour associated antigen as well as for a radio-labeled moiety is first administered followed by the radio-labeled moiety, which may be either biotin or a metal chelate. The relative merits of these are described & Rhenium-Re 186/188 , Gold-Au 199 & Lutetium-Lu 177 are suggested as candidate therapy isotopes in such pretargeting approaches.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded123    
    Comments [Add]    

Recommend this journal